CD209 and coronary artery disorder: Patients with anti‐CD209 IgM autoantibodies (Supplementary table 1) were more likely to be older (65 vs 59, P = 0.05; Figure 1b), to have CAD (44% vs 19%, P = 0.03; Figure 1c) and to have been exposed to antihypertensive medications against the renin–angiotensin–aldosterone axis (ACE inhibitors or angiotensin II receptor blockers) (52% vs 30%, P = 0.05; Figure 1d), although neither characteristic reached statistical significance.